TrakCel to supply UK’s Northern Alliance cell therapy tracking partnership

20-organisation partnership involving NHS tasked by Innovate UK to bring cell therapies to the market to be supported by supply chain platform

Cardiff, UK, April 11, 2018 – TrakCel, the industry-leading software developer for cell and gene therapy supply chain tracking and orchestration, announces today it will be the organization responsible for tracking and documentation of cell and gene therapy products for the Northern Alliance Advanced Therapies Treatment Centre.

The Northern Alliance is a partnership of advanced therapies companies, NHS organisations and academic groups in the North of England and Scotland. The partnership of twenty organisations will be led by Newcastle upon Tyne NHS Hospitals NHS Foundation Trust and the Scottish National Blood Transfusion Service. The alliance has received an Industrial Strategy Challenge Fund three-year grant award from Innovate UK. The grant totals £7 million with an expected additional £2 million contributions from commercial partners.

The Northern Alliance has been tasked with facilitating the development, commercialisation and adoption of cell, gene and tissue engineered therapies in the UK. Specifically, this collaboration will create ‘state-of-art’ infrastructure that includes technology, logistics, storage, manufacturing and supply of clinical sites, evaluation, funding and adoption.

“TrakCel now provides tracking and orchestration to numerous global cell and gene therapy companies across the industry. It is now established across the global industry that all major cell therapy projects require a traceability and management solution for operating their clinical development and furthering their commercialisation strategies,” said Ravi Nalliah, CEO, TrakCel. “As a result, the TrakCel platform will be critical to the success of the development of therapies by the Northern Alliance that could help countless patients across the UK and globally. This is a responsibility that we take
incredibly seriously.”

It is widely anticipated that the first cell therapy CAR-T product will be approved by the European Medicines Agency (EMA) in the next 12 months. The NHS will need a fully integrated network to safely and efficiently deliver these therapies. The solutions developed by the Northern Alliance will increase the capacity of the NHS to deliver these medicines by developing systems and processes within the trusts and hospitals capable of delivering advanced therapies to patients. The resultant systems could potentially be rolled out across the UK and globally.

TrakCel will provide the Northern Alliance with a digital backbone for tracking and documenting the movement of samples throughout the collection, logistics and manufacturing process. This comprehensive log of all activities will be vital for managing traceability and the chain of custody across the multiple organisations and teams involved in the partnership. TrakCel will also create a digital infrastructure across each hospital and the wider partnership to co-ordinate and manage the cell and gene therapy products.

TrakCel is dedicating a development team for the majority of the product timeline, and a project manager and business analyst throughout the project. The TrakCel senior management and the wider organization will be intensely involved throughout the project.

To learn more about TrakCel supply chain orchestration for critical cell therapy tracking, visit our solutions page.

About TrakCel

TrakCel is the market leading designer, developer and deliverer of integrated technologies specifically created in 2012 to manage the international autologous and allogeneic cell, gene and immunotherapy supply chain. TrakCel’s software platform has been developed in collaboration with, and increasingly adopted by leading companies in the cell, gene and immunotherapy industries. TrakCel’s solutions deliver real-time control over the entire therapeutic supply chain, from sample collection through manufacturing to treatment delivery. The TrakCel platform accelerates global scale-up and scale-out of cell and gene therapy products, increasing efficiency and decreasing complexity, while maintaining needle-to-needle compliance and traceability.

TrakCel is headquartered in Cardiff, Wales, UK with US offices in California and New Jersey. It aims to employ over 100 people by end of 2019, following a number of senior appointments in 2016 and 2017.

About Northern Alliance Advanced Therapies Treatment Centre

The Northern Alliance Advanced Therapy Treatment Centre (NA-ATTC), formally established in March 2018, is a consortium of twenty industry, NHS and academic organisations led by Newcastle Hospitals and the Scottish National Blood Transfusion Service (SNBTS). The purpose of the centre is to develop the systems and infrastructure required to support the delivery of cell and gene therapies with the ultimate aim of increasing patient access to advanced therapy medicinal products (ATMPs) on a national level.

For further information please contact:

Image Box PR

Neil Hunter +44 (0) 20 8943 4685

Michelle Boxall +44 (0) 20 8943 4685

More by TrakCel Marketing Team

Tour our tomorrow, today